TCR2 Therapeutics Priced, Nasdaq: TCRR

Early stage biotech developing immunotherapies for various cancers.

Industry: Health Care

Latest Trade: $18.96 -2.01 (-9.6%)

First Day Return: +0.5%

Return from IPO: +39.8%

Industry: Health Care

We are an innovative immunotherapy company developing the next generation of novel T cell therapies for patients suffering from cancer. Our proprietary TCR Fusion Construct T cells (TRuC-T cells) specifically recognize and kill cancer cells by harnessing the entire T cell receptor signaling complex, which we believe is essential for T cell therapies to be effective in patients with solid tumors. We have also designed our TRuC-T cells so that tumor cell recognition does not require human leukocyte antigens, which provides two important additional benefits. First, in contrast to current engineered T cell therapies that use the full TCR, our technology is designed so that it can be applied to all patients that express the cancer surface antigen irrespective of HLA subtype, which we believe will allow us to address a significantly larger patient population. Second, HLA is downregulated or lost in many tumors which can prevent their recognition by T cells and lead to diminished response rates and higher relapse rates. We therefore believe our approach will allow us to deliver the first HLA-independent TCR-T cell therapy for patients with solid tumors. We also believe that our product candidates have the potential to improve upon the efficacy and safety of currently approved CAR-T cell therapies in CD19-positive B-cell hematological malignancies. This belief is based on preclinical studies comparing our product candidates to CAR-T cells that we engineered.
more less
IPO News for TCR2 Therapeutics
more
IPO Data
IPO File Date 12/28/2018
Offer Price $15.00
Price Range $14.00 - $16.00
Offer Shares (mm) 5.0
Deal Size ($mm) $75
Lock-Up Date IPO Pro Only
Street Research IPO Pro Only
IPO Data
IPO Date 02/13/2019
Offer Price $15.00
Price Range $14.00 - $16.00
Offer Shares (mm) 5.0
Deal Size ($mm) $75
Lock-Up Date IPO Pro Only
Street Research IPO Pro Only
Underwriters
more
Company Data
Headquarters Cambridge, MA
Founded 2015
Employees 45
Website www.tcr2.com